Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlaxoSmithKline
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed invasive breast cancer with incurable stage IIIB, IIIC with T4 lesion or stage IV disease at primary diagnosis or at relapse after curative intent surgery.
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
Documented amplification of ErbB2 by Fluorescence in situ hybridization (FISH)
Measurable disease by Response Evaluation Criteria In Solid Tumors (RECIST)
Adequate renal, hepatic and cardiac function
You may not be if
Prior chemotherapy, immunotherapy, biologic therapy or anti-ErbB1/ErbB2 therapy other than adjuvant therapy. \[Prior neo-adjuvant or adjuvant therapy (including trastuzumab) will be allowed provided it was stopped at least 12 months before study entry.
Patients with active brain metastases
Patients with bilateral breast cancer, bone metastases as the only disease site or metastases to more than 30% of the hepatic parenchyma.
Clareo Health | Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer
